Exploratory analysis of the economically justifiable price of reslizumab for asthma severe in Colombia by Jefferson Antonio Buendía, Andres Felipe Zuluaga

Subjects: “…Reslizumab…”
Get full text

Monoclonal antibodies in severe asthma: outcomes from real-world data by Silvia del-Barrio-Buesa, Silvia del-Barrio-Buesa, Álvaro Narrillos-Moraza, Álvaro Narrillos-Moraza, Julia García-de-Pedro, Julia García-de-Pedro, Julia García-de-Pedro, Francisco Javier de-Castro-Martínez, Francisco Javier de-Castro-Martínez, María Esther Durán-García, María Esther Durán-García, Vicente Escudero-Vilaplana, Vicente Escudero-Vilaplana, Elena Lobato-Matilla, Elena Lobato-Matilla, Rosa Romero-Jimenez, Rosa Romero-Jimenez, Esther Chamorro-de-Vega, Esther Chamorro-de-Vega, Paula Ruiz-Briones, Paula Ruiz-Briones, Félix Jesús Garcia-Moreno, Félix Jesús Garcia-Moreno, María Martín-Bartolomé, María Martín-Bartolomé, Ana Herranz, Ana Herranz, María Sanjurjo, María Sanjurjo

Subjects: Get full text

Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation by S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev

Subjects: Get full text

Reslizumab versus placebo for poorly controlled, severe eosinophilic asthma: Meta-analysis by Milosavljević Miloš N., Janković Slobodan M., Pejčić Ana V., Milovanović Jasmina R., Opančina Valentina D., Kostić Marina J.

Subjects: Get full text